Loading
Led CLEOPATRA, which showed dual HER2 blockade with pertuzumab gives an unprecedented 16-month survival gain in metastatic disease.
Sandra Swain was principal investigator of CLEOPATRA, the trial establishing pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer with a median survival of 56 months. She has led NSABP trials, chaired ASCO, and published extensively on anthracycline cardiotoxicity. Her current work covers HER2-directed therapy sequencing and disparities in trial access.
Shares Trastuzumab, HER2, HER2-positive breast cancer and the tags breast, her2.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
Shares the tags breast, trialist.
Shares the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.